Info
Ripretinib
- Unique “switch control” mechanism extends the spectrum of susceptible muts to those targeted by both type I & type II kinase inhibitors (Cancer Cell 2019;35:738)
- INVICTUS phase III RCT of ripretinib vs. placebo in 4th-line setting (Lancet Onc 2020;21:923) median PFS increased (6.3 vs. 1.0 mos); common s/e-alopecia, myalgia/arthralgia, fatigue, PPES, GI toxicities, cardiotoxicity
- INTRIGUE trial will assess ripretinib vs. sunitinib in the 2nd-line setting (ongoing)